Allen, R.P., McCann, U.D., Ricaurte, G.A. (1993) Persistent effects of (+/-)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") on human sleep. Sleep, 16, 560-4 http://www.maps.org/publications/1993_allen_1.pdf
Baggott, M., Jerome, L., Stuart, R. (2001) A Review of the English-Language Scientific and Medical Literature. http://maps.org/research/mdma/protocol/mdmareview.pdf
Broening, H.W., Bowyer, J.F., Slikker, W. (2001) Age-dependent sensitivity of rats to the long-term effects of the serotonergic neurotoxicant (+/-)-3,4-methylenedioxymethamphetamine (MDMA) Coorelates With the Magnitude of MDMA Induced Thermal Response. J Pharmacol Exp Ther 275, http://www.erowid.org/references/refs_view.php?A=ShowDoc1&ID=475
Carlson, N.R. (2001) Physiology of Behavior. Massachusetts: Allyn and Bacon.
Cooper, J.R., Bloom, F.E., Roth, R.H. (1982) The Biochemical Basis of Neuropharmacology New York/Oxford: Oxford University Press.
Downing, J. (1986) The psychological and physiological effects of MDMA on normal volunteers. Journal of Psychoactive Drugs. 18,(4):335-40 http://www.erowid.org/references/refs_view.php?A=ShowDoc1&ID=548 Fineschi, V., Masti, A. (1996) Fatal poisoning by MDMA (ecstasy) and MDEA: a case report. Int J Legal Med 108, 272-275, http://erowid.org/references/refs_view.php?A=ShowDoc1&ID=142
Frederick, D.L., Paule, M.G. (1997) Effects of MDMA on complex brain function in laboratory animals. Neuroscience and Behavioral Reviews 21, 67-78, http://www.erowid.org/references/refs_view.php?A=ShowDoc1&ID=298
Gamma, A., Buck, A., Berthold, T., Vollenweider, F. (2001) No difference in brain activation during cognitive performance between Ecstasy (MDMA) users and controls: a [H2(15)O]-PET study. J Clinical Psychopharmacology, 21K(1), 66-71, http://www.erowid.org/references/refs_view.php?A=ShowDoc1&ID=588
Gijsman, H.J., Verkes, R.J. van Gerven, A., Cohen, A. (1999) MDMA study. Neuropsychopharmacology 296, 207-15, http://www.erowid.org/references/refs_view.php?A=ShowDoc1&ID=295
Granoff, M.I., Ashby, C.R. Jr. (1998) The Effect of the Repeated Administration of the Compound 3,4-methylenedioxymethamphetamine on the Response of Rats to the 5-HT2 receptor agonist +- -1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane Neuropshycobioloby 37, 36-40, http://www.erowid.org/references/refs_view.php?A=ShowDoc1&ID=286
Green, A.R., Cross, A.J., Goodwin, G.M. (1995) Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or 'Ecstasy'). PSychopharmacology 119, 247-260, http://www.erowid.org/references/refs_view.php?A=ShowDoc1&ID=625
Greer, G., Tolbert, R. (1986) Subjective reports of the effects of MDMA in a clinical setting J Psychoactive Drugs, 18(4), 319-27 http://www.erowid.org/references/references.cgi?ID=628
Greer, G., Tolbert, R. (1998) A method of conducting therapeutic sessions with MDMA J Psychoactive Drugs, 30(4), 371-9 http://www.erowid.org/references/references.cgi?ID=223
Grinspoon, L., Bakalar, J.B., (1986) Can drugs be used to enhance the psychotherapeutic process? Am J Psychother 40,(3):393-404, http://www.erowid.org/references/refs_view.php?A=ShowDoc1&ID=630
Grob, C.S., Poland, R.E., Chang, L., Ernst, T. (1996) Pyschobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. Behav Brain Res 73, 103-7, http://www.maps.org/publications/1996_grob_1.pdf
Gudelsky, G.A., Yamamoto, B.K., Nash, F. (1994) Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonsists. J Pharmacol Exp Ther 264, 225-230, http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&uid=7698172&cmd=showdetailview&indexed=google
Henry, J.A., Jeffreys, K.J., Dawling, S. (1992) Toxicity and deaths from 3,4-methylenedioxymethamphetamine ('ecstasy'). Lancet, 340, 384-387, http://www.erowid.org/references/refs_view.php?A=ShowDoc1&ID=657
Henry, J.A., Hill, I.R. (1998) Fatal interaction between ritonavir and MDMA. Lancet, 352, 1751-2, http://www.maps.org/publications/1998_henry_2.pdf
Jansen, K.L.R. (1997) Adverse psychological effects associated with the use of Ecstasy (MDMA) and their treatment. In: Ecstasy Reconsidered (Saunders, N. ed.) pp112-128. Nicholas Saunders, 14 Neal's Yard, London WC2 9DP, United Kingdom. http://www.ecstasy.org/info/karl.html
Johnson, E.A., Shvedova, A.A., Kisin, E., O'Callaghan, J.P., Kommineni, C., Miller, D.B. (2002) d-MDMA during vitamin E deficiency: effects on dopaminergic neurotoxicity and hepatotoxicity. Brain Res 933(2): 150-163. http://www.maps.org/publications/2002_johnson_1.pdf
Joseph, R. (1993) The Naked Neuron: Evolution and the Languages of the Body and Brain New York: Plenum Press.
Kirsh, M. M. (1986) Designer Drugs Minneapolis: CompCare Publications.
Leonard, B. E. (1997) Fundamentals of Psychopharmacology New York: John Wiley and Sons.
Mas, M., Farre, M., de la Torre, R., Roset, P.N., Ortuno, J., Segura, J., Cami, J. (1999) Cardiovascular and neuroendocrine effects and pharmokinetics of 3,4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 290, 136-45, http://www.maps.org/publications/1999_mas_1.pdf
McCann, U.D., Szabo, Z., Scheffel, U., Dannais, R., Ricaurte, G. (1998) Positron emission tomographic evidence of toxic effect of MDMA ('Ecstasy') on brain serotonin neurons in human beings. Early Report, http://www.emdef.orgwww.drugpolicy.org/docUploads/positronMDMA.pdf
McCann, U.D., Eligulashvili, V., Ricaurte, G.A. (2000) (+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies. Neuropsychobiology 42, 11-6, http://www.maps.org/publications/2000_mccann_1.pdf
Ricaurte, G.A., McCann, U.D. (2001) Assessing long-term effects of MDMA (Ecstasy). Lancet 368, 1864, http://erowid.org/references/refs_view.php?A=ShowDoc1&ID=1277
Mechan, A., Moran, P.M., Elliott, J.M., Young, A., Joseph, M., Green, R. (2002) A study of the effect of a single neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') on the subsequent long-term behavior of rats in the plus maze and the open field. J Pharmacol Exp Ther 159, 167-175, http://research.lycaeum.org/researchpdfs/2002_mechan_1.pdf
Milosevic, A., Agrawal, N., Redfearn, P., Mair, L. (1999) The occurrence of toothwear in users of Ecstasy Community Dent Oral Epidemiol Vol 27 (No 4), 283-287 http://www.erowid.org/references/refs_view.php?A=ShowDoc1&ID=84
Nichols, D.E. (1986) Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs 18, 305-13, http://www.maps.org/publications/1986_nichols_1.pdf
Niesink, R.J.M., Jaspers R.M.A., Kornet, L.M.W., van Ree, J.M. (1999) Drugs of Abuse and Addiction: Neurobehavioral Toxicology New York: CRC Press.
O'Shea, E., Granados, R., Esteban, B., Colado, M.I., Gree, R. (1998) The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of anministration of MDMA (ecstasy). Neuropharmacology Ther 27, 919-927, http://www.erowid.org/references/refs_view.php?A=ShowDoc1&ID=284
Pacifici, R., Zuccaro, P., Farre, M., Pichini, S., Di Carlo, S., Roset, P.N., Hernandez, L.C., Ortuno, J., Segura, J., Cami, J., de la Torre, R. (2000) Immunomodulating activity of MDMA. Ann N Y Acad Sci 914, 215-24, http://www.maps.org/publications/2000_pacifici_1.pdf
Pacifici, R., Zuccaro, P., Farre, M., Pichini, S., Di Carlo, S., Roset, P.N., Ortuno, J., Segura, J., de la Torre, R. (1999) Immunomodulating properties of MDMA alone and in combination with alcohol: a pilot study. Life Sci 65, L309-16, http://www.maps.org/publications/1999_pacifici_1.pdf
Pacifici, R., Zuccaro, P., Lopez, C.H., Pichini, S., Di Carlo, S., Farre, M., Roset, P.N., Ortuno, J., Segura, J., Torre, R.L. (2001) Acute effects of 3,4-methylenedioxymethamphetamine alone and in combination with ethanol on the immune system in humans. J Pharmacol Exp Ther 296, 207-15, http://www.maps.org/publications/2001_pacifici_1.pdf
Perrine, D.M. (1996) The Chemistry of Mind-altering Drugs: History, Pharmacology and Cultural Context Washington, DC: American Chemical Society.
Semple, D.M., Ebmeier, K.P., Glabus, M.F., O'Carroll, R.E., Johnstone, E.C.
(1999) Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ('ecstasy') users. Br J Psychiatry, 1999; 175, 63-9 http://www.erowid.org/references/refs_view.php?A=ShowDoc1&ID=63
Schmidt, C.J., Kehne, J.H. (1990) Neurotoxicity of MDMA: neurochemical effects. Ann N Y Acadademy Scientific Therapy 600, http://www.erowid.org/references/refs_view.php?A=ShowDoc1&ID=939
Schmidt, C.J., Taylor, V.L., Abbate, G., Riedezak, T. (1991) 5-HT2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine by blocking the acute stimulation of Dopamine synthesis: Reversal by L-Dopa. J Pharmacol Exp Ther 256, 230-236, http://www.erowid.org/references/refs_view.php?A=ShowDoc1&ID=944
Simeon, D. (2004). Depersonalisation disorder: A contemporary overview. CNS Drugs, 18(6), 343-354.
Woodrow, G., Harnden, P., Turney, J.H. (1995) Acute renal failure due to accelerated hypertension following ingestion of 3,4-methylenedioxymethamphetamine ('ecstasy'). Nephrol Dial Translant 10, 399-400, http://www.maps.org/publications/1995_woodrow_1.pdf
All original Calvin & Hobbes images are Bill Watterson & Universal Press Syndicate